文献速递中医内科中药与中成药合理使用

基于证候亚组辨证的中药辅助治疗帕金森病:一项先导性附加、随机、对照、实用性临床试验方案

Chinese herbal medicine treatment based on subgroup differentiation as adjunct therapy for Parkinson's disease: study protocol of a pilot add-on, randomised, controlled, pragmatic clinical trial.
PubMed 文献 · Chin Med · 2022-01-24

本研究为一项先导性评估者与数据分析者盲、附加、随机、对照、实用性临床试验方案,计划招募160例帕金森病患者并按1:1随机分为治疗组与对照组。治疗组依据中医证候分层给予相应中药并联合常规西药,对照组仅用常规西药,主要结局为MDS-UPDRS第Ⅱ部分。研究旨在初步评估辨证中药对帕金森病症状与生活质量的效果,并评价未来大规模试验设计的可行性。

要点

  • 治疗组按中医证候分层给予中药,联合常规西药,对照组仅用常规西药。
  • 主要结局为MDS-UPDRS第Ⅱ部分,次要结局含MDS-UPDRS部分及总分、NMSS各域及总分。
  • 研究为32周先导试验,旨在为未来大规模试验提供初步数据与设计依据。

核心结论

  • 该先导试验旨在初步评估基于证候辨证的中药对帕金森病症状与生活质量的效果,并评价实用性试验设计的可行性。
  • 试验成功将表明含证候亚组分层的实用性设计可行且能产生可靠结果,并为未来大规模临床研究提供初步数据。

研究设计与样本

  • 本研究为一项先导性评估者与数据分析者盲、附加、随机、对照、实用性临床试验。
  • 计划招募160例帕金森病患者,按1:1比例随机分为治疗组与对照组,试验持续32周。

关键数值与推荐

  • 治疗组患者依据中医证候分层并给予相应中药,同时联合常规药物治疗;对照组仅接受常规药物治疗。
  • 主要结局为MDS-UPDRS第Ⅱ部分,次要结局包括MDS-UPDRS部分及总分、NMSS各域及总分。
  • 不良事件通过每月随访和问卷进行监测,数据采用混合模型由Jamovi和R分析。

临床怎么用

  • 本方案为研究性干预,尚不能提供临床疗效结论;临床实践应继续以常规药物治疗为基础。
  • 中药使用需基于中医证候辨证分层,并由后续试验结果验证其辅助治疗价值。

局限性

  • 本文件为试验方案,尚未报告实际研究结果与疗效数据。
  • 作为先导试验,样本量有限,主要目的是评价设计可行性与为未来大规模研究提供初步数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Parkinson's disease (PD) is a prevalent and debilitating condition. Conventional medications cannot control all symptoms and may inflict adverse effects. A survey reported that Chinese herbal medicine (CHM) is frequently sought. Existing CHM trials were contradictory and often of poor quality due to lack of methodological rigor. A national clinical guideline was drafted in China with diagnostic criteria and treatment strategy of Chinese medicine (CM) patterns subgroups of PD. The suggested CHM were found to exhibit neuroprotective effect in in vitro and in vivo studies. This trial aims to preliminarily assess the effect of CHM prescribed based on pattern differentiation on PD symptoms and patients' quality of life, and evaluate the feasibility of the trial design for a future large-scale trial. METHODS: This trial will be a pilot assessor- and data analyst blind, add-on, randomised, controlled, pragmatic clinical trial. 160 PD patients will be recruited and randomised into treatment or control groups in a 1:1 ratio. The trial will be conducted over 32 weeks. PD patients in the treatment group will be stratified into subgroups based on CM pattern and receive CHM accordingly in addition to conventional medication (ConM). The control group will receive ConM only. The primary outcome will be part II of the Movement Disorder Society Sponsored Revision of Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Secondary outcomes will include part and total scores of MDS-UPDRS, domain and total scores of Non-motor symptom scale (NMSS). Adverse events will be monitored by monthly follow-ups and questionnaires. Mixed models will be used to analyse data by Jamovi and R. EXPECTED OUTCOMES: The success of our trial will show that the pragmatic design with subgroup differentiation is feasible and can produce reliable results. It will also provide preliminary data of the effect of CHM on improving clinical outcomes and quality of PD patients. Data collected will be used to optimize study design of the future large-scale clinical study. ETHICAL CLEARANCE: Ethical clearance of this study was given by the Research Ethics Committee of Hong Kong Baptist University (REC/20-21/0206). Trial registration This trial is registered on ClinicalTrials.gov (NCT05001217, Date: 8/10/2021, https://clinicaltrials.gov/ct2/show/NCT05001217 ). Type of manuscript: clinical trial protocol (date: 3rd November, 2021, version 1).

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Yuen SCS, Chua KK, Zhong LLD, et al. Chinese herbal medicine treatment based on subgroup differentiation as adjunct therapy for Parkinson's disease: study protocol of a pilot add-on, randomised, controlled, pragmatic clinical trial. Chin Med. 2022. PMID: 35073963. doi:10.1186/s13020-022-00572-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。